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Background: Low levels of plasma 25-hydroxyvitaminD (25(OH)D) are associated with a higher incidence of
multiple sclerosis (MS) due to the immune suppressive properties of vitamin D.
The aim of this study was to determine the correlation between plasma 25(OH)D concentrations and clinical and
immunological variables in a cohort of multiple sclerosis patients.
Methods: Plasma 25(OH)D concentrations were evaluated in summer and winter in 15 primary progressive MS
(PPMS) patients, 40 relapsing- remitting MS (RRMS) patients and 40 controls (HC). Protocol variables included
demographic and clinical data, radiological findings and immunological variables (oligoclonal bands, HLADR15 and
T-lymphocyte proliferation to a definite mix of 7 myelin peptides).
Results: During the winter, plasma concentrations were significantly lower in RRMS patients compared to HC,
whereas no differences were found in summer. No relationships were found between plasma 25(OH)D
concentrations and clinical or radiological variables. RRMS patients with a positive T-cell proliferation to a mix of
myelin peptides (n = 31) had lower 25(OH)D concentrations.
Conclusions: 25(OH)D is an immunomodulatory molecule that might have a regulatory role in T-cell proliferation
to myelin peptides in RRMS patients.
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Multiple sclerosis (MS) is a chronic inflammatory, neu-
rodegenerative disease of the central nervous system of
unknown aetiology [1]. It is currently considered to be a
multi-causal, autoimmune disease, with genetic and en-
vironmental factors playing a role. Vitamin D deficiency
has long been considered a possible causal factor of MS
owing to the apparent inverse relationship between MS
prevalence and sun exposure, a major factor in the pro-
duction of vitamin D in humans [2,3]. Vitamin D is a
modulator of calcium homeostasis; however, its role in
the pathogenesis of MS is explained by its strong im-
mune modulating potential. Vitamin D exerts a direct* Correspondence: laiagrlo@gmail.com
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distribution, and reproduction in any mediumeffect on T-lymphocyte proliferation against myelin pep-
tides, cytokine production and cell-cycle progression [4].
Moreover, direct effects of vitamin D on dendritic cells
(DC) have also been described. Vitamin D-conditioned
DC are able to suppress Th1 cell proliferation and in-
duce apoptosis [5,6].
Recent works studied serum levels of vitamin D meta-
bolites in MS patients. Low 25(OH)D levels in healthy
adolescents have been associated with a higher risk of
developing MS in later life [7]. Moreover, recent obser-
vational studies established an association between vita-
min D level status and clinical or immunological
variables. MS patients with lower vitamin D levels have
been shown to have a higher relapse risk and greater dis-
ability [8-10]. High 25(OH)D levels have also been asso-
ciated with improved Treg function and with skewing of
the Th1/Th2 balance towards Th2 [11]. However, clinicalntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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provement in MS patients treated with vitamin D com-
pounds [12]. Therefore, the relationship between plasma
25(OH)D concentrations and different clinical or im-
munological parameters of the disease need to be further
characterised.
The aim of this study was to compare plasma 25(OH)
D concentrations between MS patients and healthy con-
trols (HC). The relationship between plasma 25(OH)D
concentrations and clinical, radiological and immuno-
logical variables of MS patients was also assessed.
Methods
Patients
Patients of Catalonia (Spain) were clinically diagnosed
with MS according to McDonald’s criteria [13]. Patients
were subdivided into two groups: relapsing -remitting
multiple sclerosis (RRMS) (n = 40) and primary progres-
sive multiple sclerosis (PPMS) (n = 15); the clinical
course of the disease was defined following Lublin and
Reingold (1996) criteria. Recruitment was limited to
men and women aged 18 to 55 years, with an Expanded
Disability Status Scale (EDSS) of 0 to 5.5 [14]. Exclusion
criteria included relapse, treatment with dietary supple-
ments, immunosuppressive therapies at any time prior
to enrolment and treatment with interferon beta, glatira-
mer acetate and corticosteroids within the previous 3
months. Forty HC with no significant demographic dif-
ferences (place of residence, race/ethnicity, age and sex)
compared with RRMS patients were selected. PPMS
patients are usually older than RRMS and more fre-
quently men than women. All donors gave their written
informed consent and the study was approved by
the Ethics Committee of Clinical Research of Hospital
Germans Trias i Pujol (reference number: EO-06-030).
Protocol variables
Protocol variables included demographic data (sex, age),
neurological dysfunction (defined according to EDSS
scale), number of previous relapses, annualised relapse
rate, years of evolution, number of contrast-enhancing
lesions and number of T2 lesions on brain magnetic res-
onance imaging (MRI) performed, for this study, within
the three months prior to the winter months and during
the winter months (from September to February). Brain
MRI scans were performed in all patients with a 1.5-
Tesla whole-body MRI (Philips) according to a
previously-established protocol including T1-weighted
spin-echo axial slices with and without the application
of gadolinium, T2-weighted spin-echo axial slices and
fluid-attenuated inversion recovery (FLAIR). Immuno-
logical variables included HLA-DR15 (performed by
Polymerase Chain Reaction, Olerup SSP™ HLA low
resolution), oligoclonal bands in cerebrospinal fluid(performed with the kit Helena BioSciences Europe,
United Kingdom) and T-lymphocyte proliferation to a def-
inite mix of 7 myelin immunodominant MS-related pep-
tides (MBP13-32, MBP111-129, MBP146-170, MBP83-99,
MOG1-20, MOG35-55, PLP139-154), performed during
winter months, at concentrations of 10 μM of each pep-
tide as previously described [15]. Twelve replicate wells
with 10 μM of each peptide plus twelve without antigen
(negative control) were prepared. After 6 days, cells were
pulsed for 16 hours with 1 μCi/well 3[H] thymidine
(Amersham, GE, Healthcare). Proliferation was deter-
mined as a function of incorporated radioactivity (cpm)
and measured by scintillation counting (1450 Microbeta;
Trilux Wallac, Finland). Individual wells were considered
positive when cpm were more than 3-fold the standard
deviation (SD) over the average cpm of the 12 negative
control wells. Individuals showing≥ 50% positive wells
were classified as responders and the remainder as non-
responders.
Blood samples
Data and blood samples were collected at two time
points: during winter months (December, January and
February) and during summer months (June, July and
August). The same patients were sampled in both
seasons.
Blood samples were obtained by venepuncture. After
centrifugation, plasma was aliquoted and frozen at −80°C
until assayed for 25(OH)D. Plasma 25(OH)D concen-
trations were measured using a competitive electro-
chemiluminescence immunoassay with the Roche
Elecsys vitamin D3 (25-OH) on a Roche Modular E170
analyser. Inter-assay coefficient of variation (CV) was
6.7% and 5.0% at serum concentrations of 24.3 ng/ml
and 39.6 ng/ml, respectively. Assay sensitivity was 4
ng/mL. The reference range for plasma 25(OH)D con-
centrations was 15.5 - 41.7 ng/mL
Statistical analysis
25(OH)D concentrations were categorised as: plasma
concentrations <20 ng/ml considered “insufficient” and
plasma 25(OH)D concentrations ≥20 ng/ml considered
“sufficient” as reported previously [16]. This cut-off for
25(OH)D was arbitrarly selected because a concentration
<20 ng/mL has been accepted as deficient for the main-
tenance of adequate calcium metabolism [17]. However,
the optimal level for other vitamin D functions remains
uncertain and might be higher (>30 ng/ml or even >40
ng/mL). Plasma 25(OH)D concentrations were also ana-
lysed as a continuous variable.
Departure from normality was assessed using the
Kolmogorov–Smirnov distribution test. Descriptive
results are expressed as mean and standard deviation
(SD) or median and interquartile range (IR).
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tions were tested for differences between MS patients
and HC using the Mann–Whitney U test. In MS
patients, the association between plasma 25(OH)D con-
centrations and age, number of relapses, years of disease
evolution, EDSS score, number of T2 and contrast-
enhancing lesions was calculated using Spearmans cor-
relation. The relationship between plasma 25(OH)D
concentrations and T-lymphocyte proliferation against
myelin peptides (yes/no) was measured using the
Mann–Whitney U test.
As a dichotomous variable (sufficient/insufficient 25
(OH)D), chi-square analyses or Fisher’s exact tests were
applied to analyse the relationship of T lymphocyte pro-
liferation against myelin peptides (yes/no) and the
Mann–Whitney U test was applied to analyse the associ-
ation with age, EDSS, years of evolution, number of pre-
vious relapses, annualised relapse rates, number of
contrast-enhancing lesions and number of T2 lesions.
The independent influence of baseline characteristics on
plasma 25(OH)D concentrations was assessed by logistic
regression analysis. Variables related to lower plasma 25
(OH)D concentrations in the univariate analysis with a P
value < 0.05 were included in the model (Enter
approach).
Differences in some of the variables between seasons
were analysed using paired statistical analyses such as
the Wilcoxon test.
All statistical analyses were performed using the Statis-
tical Package for Social Sciences (SPSS/Windows version
17.0; SPSS Inc. Chicago, IL, USA). P values < 0.05 were
considered significant.
Results
Clinical characteristics of subjects
Ninety-five subjects were assessed: 40 RRMS patients,
15 PPMS patients and 40 HC. Demographic and clinical
characteristics of patients and controls are summarised
in Table 1. Thirty-five patients (87%) of the RRMS group
were women. Mean age of RRMS patients at inclusion
was 40 years (± 7.8), median EDSS 2.5 [1.5-3.5] and
mean disease duration 11 years (± 6.7). Of the PPMSTable 1 Demographic and clinical characteristics of the
study population
RRMS PPMS HC
N 40 15 40
Age (Years) a 40 ±7.8 48.5 ±12.7 38 ±6.8
Female (%) 87% 45% 75%
EDSS 2.5 [1.5-3.5] 3.5 [2.0-5.5] ——————
Disease duration (yrs) 11 ±6.7 10 ±5.3 ——————
a. Values are expressed as mean ± SD. RRMS= relapsing-remitting multiple
sclerosis; PPMS=primary progressive multiple sclerosis; HC=healthy controls;
EDSS= expanded disability status scale.group, 7 patients (45%) were women. Mean age of
PPMS patients at inclusion was 48.5 years (± 12.7),
median EDSS 3.5 [2.0-5.5] and mean disease duration
10 years (± 5.3). Thirty patients (70%) of the HC
group were women. Mean age of HC at inclusion was
38 years (± 6.8).Plasma 25(OH) D concentrations between MS patients
and HC
During winter, plasma 25(OH)D concentrations were
significantly lower in RRMS patients compared to HC
(16.6 ± 7.5 ng/ml vs 24.1 ± 7.4 ng/ml, respectively,
p = 0.0001). In contrast, PPMS patients showed 25(OH)
D concentrations similar to controls (22.1 ± 6.1 ng/ml vs
22.8 ± 7.1 ng/ml, p = 0.7). Differences were not detected
during summer months between RRMS and HC
(26.2 ± 13.1 ng/ml vs 29.8 ± 11.7 ng/ml, p = 0.2) or be-
tween PPMS and HC (27.2 ± 10.3 ng/ml vs 30.5 ± 11.7
ng/ml, p = 0.6) (Figure 1).
During winter, a higher percentage of RRMS patients
had insufficient plasma 25(OH)D concentrations (<20
ng/ml) compared to HC (65% vs 45%, p = 0.033). During
summer the number of individuals with 25(OH)D defi-
ciency was low (7 RRMS patients, 2 PPMS patients and
6 HC) (data not shown).Figure 1 Plasma 25(OH)D concentrations between RRMS
patients and HC during summer and winter. Plasma 25(OH)D
concentrations (mean+ SD) were significantly lower (p = 0.0001) in
RRMS patients (n = 40) compared to HC (n = 40) during the winter
months. Differences in plasma 25(OH)D concentrations were not
detected (p = 0.2) between patients and HC during the summer
months. RRMS and HC had higher plasma 25(OH)D concentrations
in summer months compared to winter months (p = 0.05 and
p= 0.03, respectively). MS: Multiple sclerosis patients. HC: Healthy
controls.
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demographic, clinical, radiological and immunological
disease characteristics in the MS cohort
To investigate the potential pathogenic role of 25(OH)D
concentrations, demographic, clinical, immunological
and MRI data were compared among RRMS patients
with 25(OH)D sufficiency (>20 ng/ml) versus insuffi-
ciency (<20 ng/ml) at two time points: summer and
winter.
During summer, differences in demographic, clinical
and immunological variables were not found among
RRMS patients with 25(OH)D sufficiency (>20 ng/ml)
versus insufficiency (<20 ng/ml) (data not shown). T-cell
proliferation against myelin peptides was not analysed in
summer months.
During winter (Table 2), no significant differences in
demographic data were found between patients with in-
sufficient and sufficient 25(OH)D. No significant associ-
ation was found between plasma 25(OH)D and clinical
variables such as number of previous relapses or years of
evolution. However, patients with plasma 25(OH)D
<20ng/mL had higher EDSS scores than patients with
plasma 25(OH)D> 20 ng/mL (2.0 [1.5-4.5] vs 3 [1–5.0],
p = 0.02). No significant association was found between
plasma 25(OH)D concentrations and brain MRI para-
meters (number of contrast-enhancing lesions and num-
ber of lesions in T2), positivity for HLADR15 or
presence of oligoclonal bands in cerebrospinal fluid. In
contrast, 88.5% of patients with insufficient 25(OH)D
concentrations (<20 ng/ml) had positive T cell prolifera-
tion to the mix of myelin peptides, and only 35.7% of
patients with sufficient 25(OH)D concentrations (>20
ng/ml) had positive T-cell proliferation to the mix of
myelin peptides (p = 0.001). Positive T-cell proliferation
was independently associated with lower 25(OH)DTable 2 Variables associated with sufficient ((25(OH)D >20ng
concentrations in RRMS patients during winter
All patients
n = 40
Age 40 ± 7.8
% Female 35 (87%)
Years of evolution 11 ± 6.7
Number of previous relapses 6 ± 4.2
Annualised relapse rates 0.35 ±0.2
EDSS 2.5 [1–3.5]
Oligoclonal bands 23 (54%)
HLADR15 positive 8 (21%)
Proliferation of T cells to myelin peptides 28 (70%)
Number of lesions in T2 42.5 ± 36
Number of contrast- enhancing lesions 0.85 ± 2
* = statistically-significant; RRMS= relapsing-remitting multiple sclerosis; 25(OH)D= 2concentrations (odds ratio 3.1; [95% CI, 1.29–5.15]) after
adjustment for age, number of previous relapses and
EDSS score.
Plasma 25(OH)D concentrations were also analysed as
a continuous variable, and an association with demo-
graphic, clinical and radiological variables was not found
(data not shown). Nevertheless, Figure 2 demonstrates
that RRMS patients with positive T-cell proliferation
(n = 31) had lower plasma 25(OH)D concentrations than
patients with negative T-cell proliferation (n = 9)
(16.6 ± 5.2 vs 21.7 ± 5.1, p = 0.006). HC with positive T-
cell proliferation (n = 12) had similar plasma 25(OH)D
concentrations to HC with negative T-cell proliferation
(n = 28) (20.6 ± 2.2 vs 21.2 ± 3.2, p = 0.3).Discussion
The results of this study demonstrate that RRMS
patients had lower plasma 25(OH)D concentrations
compared with HC during the winter months. In agree-
ment with our results, previous studies [18] demon-
strated summer/winter differences in vitamin D status
between MS patients and HC. In our opinion, differ-
ences in plasma 25(OH)D concentrations during sum-
mer could not be detected because sun exposure in
these months led to an increase in plasma 25(OH)D
concentrations in RRMS patients to levels similar to HC.
In this study, the RRMS patients selected were not on
disease-modifying drugs (DMD) since we aimed to ana-
lyse plasma 25(OH)D concentrations, T-cell reactivity
against myelin peptides and the association between
vitamin D status and clinical, radiological and immuno-
logical variables without the interference of immunomo-
dulatory treatment. The main reasons for patients not
receiving DMD were: they did not fulfil the criteria for/ml) vs insufficient (25(OH)D) <20ng/ml) plasma
25(OH)D >20 ng/mL
n= 16
25(OH)D <20 ng/mL
n= 24
p-value
40.6 ± 9.2 41.8 ± 7.05 0.5
13 (92.9%) 22 (84.6%) 0.45
10.3 ± 7 12.1 ± 6.7 0.4
4.4 ±3.4 7.3 ± 4.2 0.08
0.4 ±0.2 0.3 ±0.2 0.2
2.0[1.5-4.5] 3[1–5.0] 0.02
9 (56.2%) 14 (58.3%) 0.28
4 (28.6%) 4 (15.4%) 0.3
5 (35.7%) 23 (88.5%) 0.001*
30.7 ± 23.7 44 ± 38 0.4
0.4 ± 0.9 1.2 ± 2.6 0.8
5hydroxyvitamin; EDSS= expanded disability status scale.
Figure 2 Plasma 25(OH)D concentrations in patients with or
without T-cell proliferation against myelin peptides. RRMS
patients were grouped according to negative or positive T-cell
reactivity. During winter, RRMS patients with positive T-cell
proliferation had lower plasma 25(OH)D concentrations (mean+ SD)
than patients with negative T-cell proliferation (p = 0.006).
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three years) or did not wish to be treated with DMD.
In this study, PPMS patients had similar plasma 25
(OH)D concentrations to HC, as previously reported [4].
Consistent with these observations, a growing body of
evidence indicates that distinct pathogenic processes
mediate brain damage in different groups of MS
patients [19].
Several efforts have been made to correlate clinical,
radiological and immunological MS data with plasma 25
(OH)D concentrations Reviewed in [20]. However, a re-
lationship between vitamin D and clinical activity of the
disease has not been established. In accordance with our
results, a significant correlation of plasma 25(OH)D with
gadolinium-enhanced or T2-weighted MRI has not been
reported. In contrast, previous studies demonstrated a
correlation between low 25(OH)D levels and high EDSS
score or an increased risk of relapse [8-10], which con-
curred with our observation that patients with 25(OH)D
insufficiency had higher EDSS scores than those with
sufficient 25(OH)D. We believe there are two possible
explanations. Low 25(OH)D levels could induce a
greater neurological disability due to an aetiopathogenic
factor. Disabled patients with high EDSS have loss of au-
tonomy, gait impairment and a more sedentary lifestyle
than patients with low EDSS; therefore, they are less
likely to be exposed to sun, which could lead to less en-
dogenous synthesis of 25(OH)D.Furthermore, lower plasma 25(OH)D concentrations
were observed in patients with positive T-cell prolifera-
tion against myelin peptides who had a higher number
of previous relapses and greater disability than unre-
sponsive patients. A limitation of this study is that our
cohort was too small to permit a definitive assessment
of the clinical outcome measures. However, we believe
increasing 25(OH)D levels exert a possible beneficial ef-
fect on improving not only immunological variables such
as T-cell proliferation against myelin peptides but also
the clinical parameters. In this context, previous studies
[12] reported that MS patients treated with vitamin D
supplements had a reduced number of relapse events
and a persistent reduction in T-cell proliferation com-
pared to controls.
To define the role of vitamin D as an immunomodula-
tory agent, the relationship between plasma 25(OH)D
concentrations and immunological parameters such as
proliferation of T-cell reactivity against myelin peptides
was analysed in this study. Previously, we demonstrated
that T-cell proliferation against a selected mix of 7 mye-
lin peptides was more common in RRMS patients than
in HC, which supports their pathogenic significance in
MS [21]. Interestingly, patients with positive T-cell pro-
liferation against myelin peptides had low levels of
plasma 25(OH)D. Correale et al. [4] demonstrated by
in vitro coculture with 1,25(OH)2D3 that the prolifera-
tion of myelin basic protein (MBP)-specific T cells was
significantly inhibited. These results suggest that vitamin
D may play an immunomodulatory role in T-cell prolif-
eration to myelin peptides. Moreover, previous studies
reported an inhibitory effect of vitamin D on Th1 cell
function and a beneficial effect on Th2 and Treg cells
in vitro [9]. Furthermore, 1,25-(OH)2D proved to exert a
beneficial effect on clinical and histological disease fea-
tures in an experimental allergic encephalomyelitis ani-
mal model of MS [22].
Vitamin D acts through the vitamin D receptor
(VDR). Certain polymorphisms of the VDR may modify
vitamin D function. Some studies showed that poly-
morphisms are significantly more common in MS [23].
Nevertheless, other studies found no differences in VDR
gene polymorphisms between MS and control groups
[24]. A limitation of this study was that we did not de-
termine the polymorphisms of the VDR, which should
therefore be assessed in further studies on vitamin D
and MS.
Conclusions
Vitamin D is an immune modulator; however its clinical
effect in MS remains unclear. This study demonstrated
that MS patients have lower plasma 25(OH)D concen-
trations during wintertime compared to HC. Plasma 25
(OH)D concentrations were also associated with T-cell
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provide support for further research in this direction to
confirm the potential benefit of vitamin D supplements
in MS patients.
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